• S1 Episode 3: Novel Therapies in Severe Asthma Treatment: Precision Medicine, Biomarkers, and New Biologics

  • Sep 7 2022
  • Length: 25 mins
  • Podcast

S1 Episode 3: Novel Therapies in Severe Asthma Treatment: Precision Medicine, Biomarkers, and New Biologics

  • Summary

  • Drs Wechsler and Akuthota discuss novel therapies in severe asthma treatment, including precision medicine, biomarkers, and new biologic agents.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969688). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    Omalizumab https://reference.medscape.com/drug/xolair-omalizumab-343444

    Mepolizumab https://reference.medscape.com/drug/nucala-mepolizumab-1000034

    Bronchial Thermoplasty https://emedicine.medscape.com/article/2094272-overview

    Eosinophilic Asthma and Sputum Eosinophilia https://www.webmd.com/asthma/eosinophilic-asthma-defined

    Role of T2 Inflammation Biomarkers in Severe Asthma https://reference.medscape.com/medline/abstract/26574724

    Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry https://linkinghub.elsevier.com/retrieve/pii/S2213-2198(21)00311-1

    Dupilumab Prescribing Information https://www.regeneron.com/downloads/dupixent_fpi.pdf

    FDA Approves Cinqair to Treat Severe Asthma https://www.fda.gov/news-events/press-announcements/fda-approves-cinqair-treat-severe-asthma

    Benralizumab https://reference.medscape.com/drug/fasenra-benralizumab-1000213

    Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss Syndrome) https://emedicine.medscape.com/article/333492-overview

    Hypereosinophilic Syndrome https://emedicine.medscape.com/article/202030-overview

    Anti-IL-5 Therapy in Patients With Severe Eosinophilic Asthma – Clinical Efficacy and Possible Criteria for Treatment Response https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-018-0689-2

    Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-blind, Placebo-Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60988-X/fulltext

    Allergic and Environmental Asthma https://emedicine.medscape.com/article/137501-overview

    FDA Approves Maintenance Treatment for Severe Asthma https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma

    Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma https://www.nejm.org/doi/full/10.1056/NEJMoa2034975

    Efficacy and Safety of Itepekimab in Patients With Moderate-to-Severe Asthma https://www.nejm.org/doi/10.1056/NEJMoa2024257

    The Targeted Eosinophil-Lowering Effects of Dexpramipexole in Clinical Studies https://www.sciencedirect.com/science/article/abs/pii/S107997961630328X

    CRTH2 Antagonists in Asthma: Current Perspectives https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733922

    Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) https://preciseasthma.org/preciseweb/

    A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype https://clinicaltrials.gov/ct2/show/NCT04718389

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about S1 Episode 3: Novel Therapies in Severe Asthma Treatment: Precision Medicine, Biomarkers, and New Biologics

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.